Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
10:45pm, Thursday, 26'th Jan 2023 Zacks Investment Research
Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
03:01pm, Thursday, 26'th Jan 2023 Zacks Investment Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Could Gilead Sciences Stock Help You Become a Millionaire?
01:55pm, Thursday, 26'th Jan 2023 The Motley Fool
Does Gilead have enough growth potential to become a market-beating investment?
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
10:50pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
Gilead Sciences (GILD) closed the most recent trading day at $84.02, moving +0.95% from the previous trading session.
Gilead Sciences May Still Be Lowballing Q4 Guidance
12:45am, Tuesday, 24'th Jan 2023
The company is overdependent on their HIV franchise, but sales are still increasing. Their newer drugs are sparsely covered by the largest insurers but could improve.
GILD or GMAB: Which Is the Better Value Stock Right Now?
12:48pm, Monday, 23'rd Jan 2023
GILD vs. GMAB: Which Stock Is the Better Value Option?
Gilead (GILD) Gains 21% in a Year: Will the Trend Continue?
12:03pm, Monday, 23'rd Jan 2023
Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility.
Gilead Added To Our 2023 Model Portfolio (Technical Analysis)
05:33am, Monday, 23'rd Jan 2023
This is a technical analysis article. As you can see, Gilead gets high grades from Seeking Alpha ratings for Momentum, Profitability and Revisions. However, it receives low grades for Valuation and Gr
Gilead Sciences: Potential To Continue Its Upward Trend
08:58pm, Sunday, 22'nd Jan 2023
While third quarter results were not really great, Gilead Sciences could beat expectations, raised its guidance, and grew at a solid pace when excluding Veklury. Especially Biktarvy, Trodelvy, Yescart
Gilead Sciences: Finally A Breakthrough
08:48pm, Sunday, 22'nd Jan 2023
Shares of Gilead Sciences have come to life after a big third quarter. This solid earnings report is accompanied by many regulatory approvals for various products.
3 Smart Stocks to Buy if a Recession Is on the Way
06:55am, Saturday, 21'st Jan 2023
Their products will enjoy strong demand regardless of what happens with the economy.
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
04:05pm, Thursday, 19'th Jan 2023
FOSTER CITY, Calif.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2022 financial results and full year 2023 financial guidance will be
3 Stocks That Beat the S&P During the Great Recession
06:35am, Wednesday, 18'th Jan 2023
These stocks could be safe places to store your money if a recession takes place this year.
Ranking The 10 Largest Biotechs By Pipeline
12:34pm, Wednesday, 11'th Jan 2023
The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment
Top Dividend Stock: Gilead Sciences Nears Buy Point Ahead of Earnings
10:08am, Wednesday, 11'th Jan 2023
This biotech superstar is in the spotlight as it nears a buy point amid continued stability and a growing dividend. The post Top Dividend Stock: Gilead Sciences Nears Buy Point Ahead of Earnings app
